Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim
Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects
Strasbourg, France, September 30, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces the achievement of two discovery milestones in its multi-target collaboration with Boehringer Ingelheim. These milestones illustrate the ability of Domain Therapeutics to address orphan GPCRs using its proprietary platforms, DTect-All™ and bioSens-All™. Financial details were not disclosed.
“Collaborating with a partner such as Boehringer Ingelheim is a great opportunity and another excellent endorsement of our expertise with challenging GPCRs,” said Pascal Neuville, CEO of Domain Therapeutics. “We are very proud to have achieved, on time, the two first milestones of this collaboration and we look forward to building on this success.” The two companies pursue the collaboration on the ongoing projects with the final objective to nominate preclinical candidates for the treatment of neuropsychiatric diseases.
Share this article